Tandem Diabetes Care, Inc.
TNDMNASDAQHealthcare● Active
$18.47
$-0.87(-4.50%)
Market Cap$1.3B
P/E Ratio—
52W High$29.65
52W Low$9.98
Tandem Diabetes Care, Inc. (TNDM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TNDM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.30
Est. -$0.46 · +34.8%
Revenue
$0.25B
Est. $0.24B · +2.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
TNDM reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.32 | — | — | — | $0.26B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.46 | -$0.30 | +34.8% | $0.25B | $0.24B | +2.8% |
| ▲ Q1 FY2026 | Feb 19, 2026 | -$0.05 | -$0.01 | +80.0% | $0.29B | $0.28B | +4.8% |
| — Q4 FY2025 | Nov 6, 2025 | -$0.31 | -$0.31 | +0.0% | $0.25B | $0.28B | -10.0% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.40 | -$0.48 | -20.0% | $0.24B | $0.25B | -3.8% |
| ▼ Q2 FY2025 | Apr 30, 2025 | -$0.60 | -$0.67 | -11.7% | $0.23B | $0.22B | +6.5% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.25 | -$0.44 | -76.0% | $0.28B | $0.25B | +12.4% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.43 | -$0.36 | +16.3% | $0.36B | $0.25B | +44.5% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.32
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.46
EPS Surpr.
+34.8%
Revenue
$0.25B
Q1 FY2026
Feb 19, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.05
EPS Surpr.
+80.0%
Revenue
$0.29B
Q4 FY2025
Nov 6, 2025
EPS Actual
-$0.31
EPS Est.
-$0.31
EPS Surpr.
+0.0%
Revenue
$0.25B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.48
EPS Est.
-$0.40
EPS Surpr.
-20.0%
Revenue
$0.24B
Q2 FY2025
Apr 30, 2025Miss
EPS Actual
-$0.67
EPS Est.
-$0.60
EPS Surpr.
-11.7%
Revenue
$0.23B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.44
EPS Est.
-$0.25
EPS Surpr.
-76.0%
Revenue
$0.28B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.36
EPS Est.
-$0.43
EPS Surpr.
+16.3%
Revenue
$0.36B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.47 | $0.48 | $0.49 | 5 |
| Q3 FY2028 | $0.26 | $0.27 | $0.27 | 10 |
| Q2 FY2028 | $0.22 | $0.22 | $0.23 | 7 |
| Q1 FY2028 | $0.09 | $0.09 | $0.09 | 5 |
| Q4 FY2027 | $0.28 | $0.29 | $0.29 | 4 |
| Q3 FY2027 | $0.03 | $0.03 | $0.03 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.4B | $0.4B | $0.4B | 6 |
| Q3 FY2028 | $0.3B | $0.3B | $0.3B | 5 |
| Q2 FY2028 | $0.3B | $0.3B | $0.3B | 5 |
| Q1 FY2028 | $0.3B | $0.3B | $0.3B | 6 |
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 6 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +34.8% | $18.03 | $18.47 | +2.44% |
| ▲ Q1 FY2026 | Feb 19, 2026 | +80.0% | $18.94 | $18.52 | -2.22% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +0.0% | $14.67 | $13.33 | -9.13% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -20.0% | $15.15 | $14.39 | -5.02% |
| ▼ Q2 FY2025 | Apr 30, 2025 | -11.7% | $16.77 | $16.85 | +0.48% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -76.0% | $33.34 | $33.59 | +0.75% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +16.3% | $33.11 | $34.24 | +3.41% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +13.0% | $36.98 | $35.21 | -4.79% |
Q2 FY2026+2.44%
Report Date
May 7, 2026
EPS Beat/Miss
+34.8%
Price Before
$18.03
Price After
$18.47
Q1 FY2026-2.22%
Report Date
Feb 19, 2026
EPS Beat/Miss
+80.0%
Price Before
$18.94
Price After
$18.52
Q4 FY2025-9.13%
Report Date
Nov 6, 2025
EPS Beat/Miss
+0.0%
Price Before
$14.67
Price After
$13.33
Q3 FY2025-5.02%
Report Date
Aug 6, 2025
EPS Beat/Miss
-20.0%
Price Before
$15.15
Price After
$14.39
Q2 FY2025+0.48%
Report Date
Apr 30, 2025
EPS Beat/Miss
-11.7%
Price Before
$16.77
Price After
$16.85
Q1 FY2025+0.75%
Report Date
Feb 26, 2025
EPS Beat/Miss
-76.0%
Price Before
$33.34
Price After
$33.59
Q4 FY2024+3.41%
Report Date
Nov 6, 2024
EPS Beat/Miss
+16.3%
Price Before
$33.11
Price After
$34.24
Q3 FY2024-4.79%
Report Date
Aug 1, 2024
EPS Beat/Miss
+13.0%
Price Before
$36.98
Price After
$35.21
Avg Beat Reaction-2.06%
Avg Miss Reaction-1.26%
Beat Rate5 / 8 quarters
Largest Move-9.13% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TNDM ends December
Tandem Diabetes Care, Inc. (TNDM) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.30 — beating the analyst consensus of $-0.46 by +34.8%. TNDM has beaten EPS estimates for 3 consecutive quarters. The next TNDM earnings date is expected around September 1, 2026.
Each quarter, investors track TNDM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TNDM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TNDM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TNDM earnings · 5 questionsTandem Diabetes Care, Inc.'s next earnings report is expected around September 1, 2026. TNDM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TNDM historically reports after market close (AMC).
TNDM earnings datewhen is TNDM earningsTNDM next earnings datewhen does TNDM report earningsTNDM earnings calendar
▸ Source: FMP · Tandem Diabetes Care, Inc. SEC filings · US GAAP · Tandem Diabetes Care, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026